Beclomethasone Plus Prednisone in Treating Patients With Graft-Versus-Host Disease
Information source: National Cancer Institute (NCI)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Graft Versus Host Disease
Intervention: beclomethasone dipropionate (Drug); methylprednisolone (Drug); prednisone (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Memorial Sloan-Kettering Cancer Center Official(s) and/or principal investigator(s):
Miguel-Angel Perales, MD, Study Chair, Affiliation: Memorial Sloan-Kettering Cancer Center
Summary
RATIONALE: Beclomethasone combined with prednisone may be an effective treatment for
graft-versus-host disease caused by stem cell transplantation. It is not yet known if
prednisone is more effective with or without beclomethasone in treating gastrointestinal
graft-versus-host disease.
PURPOSE: Randomized phase III trial to determine the effectiveness of prednisone with or
without beclomethasone in treating patients who have graft-versus-host disease afftecting the
gastrointestinal system.
Clinical Details
Official title: A Phase III, Randomized, Placebo-Controlled, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Oral Beclomethasone 17, 21-Dipropionate (BDP) in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Grade II Graft vs. Host Disease With Gastrointestinal Symptoms
Study design: Supportive Care, Randomized, Double-Blind, Placebo Control
Detailed description:
OBJECTIVES:
- Compare the efficacy of beclomethasone dipropionate and prednisone vs placebo and
prednisone, in terms of time to treatment failure, in patients with grade II
graft-vs-host disease with gastrointestinal symptoms.
- Compare the proportion of treatment failures on study days 10, 30, 50, 60, and 80 in
patients treated with these regimens.
- Compare the cumulative systemic corticosteroid exposure in patients treated with these
regimens.
- Compare the incidence and degree of hypothalamic-pituitary-adrenal axis suppression in
patients treated with these regimens who have not experienced treatment failure by study
day 50.
- Compare the safety of these regimens in these patients.
- Compare the total deaths and causes of death through 200 days post-transplantation of
patients treated with these regimens.
- Assess the pharmacokinetic profile of beclomethasone dipropionate in these patients.
OUTLINE: This is a randomized, double-blind, placebo-controlled, parallel, multicenter study.
Patients are stratified according to graft tissue source (2 HLA haplotype-identical sibling
vs all others) and topical steroid use at baseline (yes vs no). Patients are randomized to 1
of 2 treatment arms.
- Arm I: Patients receive oral beclomethasone dipropionate 4 times daily on days 1-50.
Patients also receive oral prednisone (or methylprednisolone IV) twice daily on days
1-10 with a rapid taper on days 11-17 followed by low-dose prednisone on days 18-80.
- Arm II: Patients receive oral placebo 4 times daily on days 1-50. Patients also receive
prednisone (or methylprednisolone) as in arm I.
In both arms, treatment continues in the absence of poorly controlled GVHD at day 10 or
unacceptable toxicity.
Patients are followed at days 51, 60, and 80 and then at 200 days post-transplantation.
PROJECTED ACCRUAL: A total of 130 patients (65 per treatment arm) will be accrued for this
study.
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
DISEASE CHARACTERISTICS:
- Histologically confirmed graft-vs-host disease (GVHD) with gastrointestinal symptoms
- Endoscopic evidence of grade II intestinal GVHD without another plausible
etiology
- Confirmed by biopsy of colon, stomach, small intestine, esophagus, or skin within
72 hours prior to study entry
- At least 10 days post allogeneic hematopoietic stem cell transplantation
- Received prior anti-candidal prophylaxis of the oropharynx with an effective drug
- Confirmed absence of intestinal infection within the past 7 days
- No liver GVHD with bilirubin greater than 3 mg/dL
- No skin GVHD other than a slowly evolving rash that involves no more than 50% of the
body surface
- No more than 1,000 mL/day of diarrhea on any 1 day within the past 3 days
PATIENT CHARACTERISTICS:
Age
- Not specified
Performance status
- Not specified
Life expectancy
- At least 3 months
Hematopoietic
- Not specified
Hepatic
- See Disease Characteristics
Renal
- Not specified
Other
- HIV negative
- Able to swallow tablets
- No multi-organ failure
- No sepsis syndrome
- No other condition with high mortality
- No infection of the mouth or esophagus with a fungal organism
- No persistent vomiting of oral intake
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Disease Characteristics
- At least 30 days since prior biologic agents
Chemotherapy
- Not specified
Endocrine therapy
- At least 30 days since prior systemic (oral or parenteral) prescription
corticosteroids administered for prophylaxis or treatment of GVHD or another
inflammatory disease process
- Concurrent dexamethasone as an antiemetic or to lessen side effects during medication
or blood product administration allowed
Radiotherapy
- Not specified
Surgery
- See Disease Characteristics
Other
- No prior beclomethasone dipropionate
- At least 30 days since prior investigational drugs or devices
- Concurrent immunosuppressants (e. g., cyclosporine, tacrolimus, sirolimus,
methotrexate, or mycophenolate mofetil) allowed for GVHD prophylaxis
Locations and Contacts
Memorial Sloan-Kettering Cancer Center, New York, New York 10021, United States
Roswell Park Cancer Institute, Buffalo, New York 14263-0001, United States
Additional Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Starting date: April 2002
Last updated: May 23, 2008
|
